United States · Research startup
United States · Ansun Biopharma, Inc.
Ansun Biopharma, Inc.
Funding reportedLast round: Series B
About Ansun Biopharma, Inc.
Ansun Biopharma, Inc.
is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2003 by virologists Dr. Mang Yu and Dr. Fang Fang, the company focuses on developing innovative, host-directed anti-viral biologics aimed at treating severe viral infections and cancer. With a dedicated team of around 25 to 27 employees, Ansun's mission is to create therapeutics that address unmet medical needs, particularly for vulnerable patient populations. The company's lead product, DAS181, is a multi-function sialidase fusion protein designed to block viral infections by cleaving sialic acid receptors from host respiratory cells. DAS181 is currently in Phase 3 clinical trials for treating Parainfluenza Virus and advancing in Phase IIB trials for severe Influenza. Ansun also explores therapies for oncology and autoimmune diseases using its sialidase platform. The company has secured significant funding, including a $50 million contract from the NIH and multiple financing rounds, to support its development efforts.
What company datasets say Ansun Biopharma, Inc. raised
Funding, as reported
Founders and team
From the SEC filings it signed: 2 on the team.
- Nancy ChangExecutive Officer, Directori
- Yining ZhaoExecutive Officeri
On the board, as filediAimin WuAllen ChaoDave ChennDonald PayneKaren LiuMichael ChangMichael ChaoYi Shi
On 2 portfolio pages
Investors who name them
Each firm lists Ansun Biopharma, Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
health carehost-directed therapysialidase enzymehost receptor targetingbiotechnology researchhost-targeted antiviralhealthcaredas181biopharmaceutical developmentimmunocompromised patientsviral entry inhibitionrespiratory infection therapysialic acid biologypharmaceuticalsinfluenza treatmentrespiratory viruses
Built with from their website
Google MapsWhatsApp Business ChatPriority HintsSlider RevolutionWordPress.orgMicrosoft ExchangeMicrosoft 365Font AwesomeApacheMySQL
+8 more
YouTubeApache HTTP ServerOutlookMicrosoft 365 Apps & ServicesPHPViewport MetaBarracuda Email Security ServiceMobile Friendly
- Sector
- Research
- Industry code
- NAICS 541714, SIC 2834, 8731
- Region
- California
- Revenue
- $8.0M a year, as listed
- Full record
- Every detail in the company directory
Research in United States
Startups like it
OpenAISan Francisco · founded 2011Raised
Retro BiosciencesRedwood City · founded 2021Raised
NewLimitSouth San Francisco · founded 2022Raised
PathosNew York · founded 2022Raised
Colossal BiosciencesDallas · founded 2021Raised
OratomicSouth PasadenaRaised
Beeline MedicinesStamford · founded 2025Raised
Element BiosciencesSan Diego · founded 2017Raised
Is this your company?
Add your raise, your deck and your story, and put Ansun Biopharma, Inc. in front of investors. Or tell us what we have wrong.